Literature DB >> 1404612

Coexpression of the simian immunodeficiency virus Env and Rev proteins by a recombinant human adenovirus host range mutant.

S M Cheng1, S G Lee, M Ronchetti-Blume, K P Virk, S Mizutani, J W Eichberg, A Davis, P P Hung, V M Hirsch, R M Chanock.   

Abstract

Recombinant human adenoviruses (Ads) that replicate in the intestinal tract offer a novel, yet practical, means of immunoprophylaxis against a wide variety of viral and bacterial pathogens. For some infectious agents such as human immunodeficiency virus (HIV), the potential for residual infectious material in vaccine preparations must be eliminated. Therefore, recombinant human Ads that express noninfectious HIV or other microbial proteins are attractive vaccine candidates. To test such an approach for HIV, we chose an experimental model of AIDS based on simian immunodeficiency virus (SIV) infection of macaques. Our data demonstrate that the SIV Env gene products are expressed in cultured cells after infection with a recombinant Ad containing both SIV env and rev genes. An E3 deletion vector derived from a mutant of human Ad serotype 5 that efficiently replicates in both human and monkey cells was used to bypass the usual host range restriction of Ad infection. In addition, we show that the SIV rev gene is properly spliced from a single SIV subgenomic DNA fragment and that the Rev protein is expressed in recombinant Ad-SIV-infected human as well as monkey cells. The expression of SIV gene products in suitable live Ad vectors provides an excellent system for studying the regulation of SIV gene expression in cultured cells and evaluating the immunogenicity and protective efficacy of SIV proteins in macaques.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1404612      PMCID: PMC240168     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Selective infection of human CD4+ cells by simian immunodeficiency virus: productive infection associated with envelope glycoprotein-induced fusion.

Authors:  S Koenig; V M Hirsch; R A Olmsted; D Powell; W Maury; A Rabson; A S Fauci; R H Purcell; P R Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

2.  An African primate lentivirus (SIVsm) closely related to HIV-2.

Authors:  V M Hirsch; R A Olmsted; M Murphey-Corb; R H Purcell; P R Johnson
Journal:  Nature       Date:  1989-06-01       Impact factor: 49.962

3.  The rev (trs/art) protein of human immunodeficiency virus type 1 affects viral mRNA and protein expression via a cis-acting sequence in the env region.

Authors:  M Hadzopoulou-Cladaras; B K Felber; C Cladaras; A Athanassopoulos; A Tse; G N Pavlakis
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

4.  Genetic analysis of mRNA synthesis in adenovirus region E3 at different stages of productive infection by RNA-processing mutants.

Authors:  B M Bhat; W S Wold
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

5.  Selective extraction of polyoma DNA from infected mouse cell cultures.

Authors:  B Hirt
Journal:  J Mol Biol       Date:  1967-06-14       Impact factor: 5.469

6.  Immunization by selective infection with type 4 adenovirus grown in human diploid tissue culture. II. specific protective effect against epidemic disease.

Authors:  W P Edmondson; R H Purcell; B F Gundelfinger; J W Love; W Ludwig; R M Chanock
Journal:  JAMA       Date:  1966-02-07       Impact factor: 56.272

7.  Role of early region 3 (E3) in pathogenesis of adenovirus disease.

Authors:  H S Ginsberg; U Lundholm-Beauchamp; R L Horswood; B Pernis; W S Wold; R M Chanock; G A Prince
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

8.  Expression of hepatitis B surface antigen with a recombinant adenovirus.

Authors:  A R Davis; B Kostek; B B Mason; C L Hsiao; J Morin; S K Dheer; P P Hung
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

9.  Recombinant adenovirus induces antibody response to hepatitis B virus surface antigen in hamsters.

Authors:  J E Morin; M D Lubeck; J E Barton; A J Conley; A R Davis; P P Hung
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

10.  Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7.

Authors:  F H Top; E L Buescher; W H Bancroft; P K Russell
Journal:  J Infect Dis       Date:  1971-08       Impact factor: 5.226

View more
  16 in total

1.  Costimulatory protein B7-1 enhances the cytotoxic T cell response and antibody response to hepatitis B surface antigen.

Authors:  X S He; H S Chen; K Chu; M Rivkina; W S Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge.

Authors:  S L Buge; E Richardson; S Alipanah; P Markham; S Cheng; N Kalyan; C J Miller; M Lubeck; S Udem; J Eldridge; M Robert-Guroff
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Utilizing the antigen capsid-incorporation strategy for the development of adenovirus serotype 5-vectored vaccine approaches.

Authors:  Linlin Gu; Anitra L Farrow; Alexandre Krendelchtchikov; Qiana L Matthews
Journal:  J Vis Exp       Date:  2015-05-06       Impact factor: 1.355

4.  Adenoviral Type 35 and 26 Vectors with a Bidirectional Expression Cassette in the E1 Region Show an Improved Genetic Stability Profile and Potent Transgene-Specific Immune Response.

Authors:  Marija Vujadinovic; Kerstin Wunderlich; Benoit Callendret; Marina Koning; Mark Vermeulen; Barbara Sanders; Esmeralda van der Helm; Adile Gecgel; Dirk Spek; Karin de Boer; Masha Stalknecht; Jan Serroyen; Maria Grazia Pau; Hanneke Schuitemaker; Roland Zahn; Jerome Custers; Jort Vellinga
Journal:  Hum Gene Ther       Date:  2017-11-30       Impact factor: 5.695

5.  Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.

Authors:  S L Buge; L Murty; K Arora; V S Kalyanaraman; P D Markham; E S Richardson; K Aldrich; L J Patterson; C J Miller; S M Cheng; M Robert-Guroff
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

Review 6.  Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development.

Authors:  L Jean Patterson; Marjorie Robert-Guroff
Journal:  Expert Opin Biol Ther       Date:  2008-09       Impact factor: 4.388

7.  Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.

Authors:  Jun Zhao; Joel Pinczewski; Victor R Gómez-Román; David Venzon; V S Kalyanaraman; Phillip D Markham; Kristine Aldrich; Matthew Moake; David C Montefiori; Yuanmei Lou; George N Pavlakis; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.

Authors:  L Jean Patterson; Nina Malkevitch; Joel Pinczewski; David Venzon; Yuanmei Lou; Bo Peng; Cindy Munch; Melissa Leonard; Ersell Richardson; Kristine Aldrich; V S Kalyanaraman; George N Pavlakis; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting.

Authors:  L Jean Patterson; Nina Malkevitch; David Venzon; Joel Pinczewski; Victor Raúl Gómez-Román; Liqun Wang; V S Kalyanaraman; Phillip D Markham; Frank A Robey; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  Packaging capacity and stability of human adenovirus type 5 vectors.

Authors:  A J Bett; L Prevec; F L Graham
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.